Murdoch research finds Chagas cure October 18, 2011 Chagas disease is spread through bites from insects such as Rhodnius prolixus - the "kissing bug". Image: Wikipedia A Murdoch University international collaborative project has found a potential cure for the deadly Chagas disease. Chagas affects eight to 10 million people in Latin American countries, with about 20,000 deaths attributed to the disease each year. Professor Andrew Thompson from Murdoch’s School of Veterinary and Biological Sciences led the parasite component of the study, which has stemmed from 25 years of research on parasite infections in humans. “Chagas disease can affect a number of organs including the heart and intestine causing acute heart failure or chronic diseases affecting the heart or digestive system that may last for decades,” Professor Thompson said. “We have developed a new compound that cures Chagas disease in our mouse model of the disease; the next step is human trials.” Professor Thompson, in partnership with Australian drug research company Epichem, is investigating infections caused by trypanosome parasites, which cause a range of diseases in developing countries, including Chagas disease, sleeping sickness, and leishmaniasis. The diseases are transmitted by different species of biting insects, and are increasingly present in Australia through migration of people and pets, exposure to defence force personnel and tourists and the emergence of similar diseases in native wildlife. “These diseases cause devastating illness and death in people,” Professor Thompson said. “There are few, if any drugs available that can cure these diseases, and in many cases the toxic side effects of the drugs are sometimes worse than the diseases they treat. “There is clearly a desperate need for new, effective, non-toxic drugs to treat and cure these diseases.” The Murdoch-Epichem partnership was initiated after international aid agency Medecins Sans Frontieres contacted Professor Thompson after reading about his research online and suggested Murdoch might be an ideal candidate for funding from Drugs for Neglected Diseases Initiative (DNDi) in Geneva, a non-profit agency directing funds from aid agencies and foundations for research on neglected diseases. “We applied to DNDi for funding and were successful, and have received financial support from DNDi for the last six years, including recent substantial funding from an ARC Linkage grant with DNDi as the partner organisation,” Professor Thompson said. “The research has led to sustained, fruitful collaboration with Epichem, as well as more recently with the Centre for Drug Optimisation at Monash University who are key collaborators on the latest Linkage grant.” Print This Post Media contact: Jo Manning Tel: (08) 9360 2474 | Mobile: 0408 201 309 | Email: email@example.com Categories: General, Teaching and Learning, Murdoch achievements, Health, biomedicine and psychology, Experts, International, School of Veterinary and Biomedical Sciences Research Tags: andrew thompson, andy thompson, arc linkage grant, chagas disease, dndi, drugs for neglected diseases initiative, epichem, latin america, leishmaniasis, medecins sans frontieres, parasitology, school of vetinary and biomedical sciences, sleeping sickness, south america, trypanasome parasites Comments (One response) Pedro March 30, 2013 Dear Prof. Thompson, I congratulate you on your work towards a cure to this horrible disease, my father who is know 60 years old contracted Chagas disease at his childhood and since then has being struggling with it, I would love to know if you could please suggest me any treatment or possible cure?I greatly appreciate your time and kindness on this matter, my best regards. Pedro Mar del Plata, Buenos Aires, Argentina Leave a comment Name (required) Mail (will not be published) (required) Website You can use these tags : <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> We read every comment and will make every effort to approve each new comment within one working day. To ensure speedy posting, please keep your comments relevant to the topic of discussion, free of inappropriate language and in-line with the editorial integrity of this newsroom. If not, your comments may not be published. Thanks for commenting!